Biodegradable Drug Eluting Stents Market Size, Share, Growth, Trends, and Global Industry Analysis: By Material ( Metallic Alloy Stents, Polymeric Stents), By Application (Coronary Artery Disease, Peripheral Artery Disease), By End-User (Hospitals Cardiac Centers) and Region Forecast 2020-2031

Biodegradable Drug Eluting Stents Market size was valued at US$ 6.6 billion in 2024 and is expected to reach US$ 10.1 billion by 2031, growing at a significant CAGR of 6.3% from 2025-2031. Drug-eluting stents are peripheral or coronary stents placed into narrowed peripheral or coronary arteries that slowly release the drug to block cell proliferation. Generally, these devices are made up of metal and remain permanently or removed through further surgery. Metal stents present drawbacks such as the predisposition to late stent thrombosis, impairment of imaging with multislice CT, hindrance of surgical revascularization. Biodegradable drug-eluting stents are made up of material that dissolves or absorbed in the body, these are temporary, and no need for further surgery to removal of the stent. These are also called as bioresorbable stents or naturally- dissolving stents.

Key Developments

• On May 02 2024: Abbott, the global healthcare company, announced the launch of XIENCE Sierra™ Everolimus (drug) Eluting Coronary Stent System in India. XIENCE Sierra is one of the latest generation stents in the XIENCE™ family, now available to people suffering from blocked coronary arteries. For interventional cardiologists, it brings unparalleled safety to the most complex cases. This coronary stent offers an innovative design, advanced technology, and best-in-class deliverability. XIENCE Sierra demonstrates flexibility and precision, enabling physicians to access and unblock difficult-to-treat blockages
• On May 13 2022: Medtronic plc , a global leader in healthcare technology, announced that it has received U.S. Food and Drug Administration (FDA) approval for the Onyx Frontier™ drug-eluting stent (DES). As the latest evolution in the Resolute DES family, Onyx Frontier DES leverages the same best-in-class stent platform as Resolute Onyx™ DES, with an enhanced delivery system1 designed to improve deliverability and increase acute performance2 in even the most challenging of cases
• In October 2015, Boston Scientific Corporation received U.S. Food and Drug Administration (FDA) approval for the synergy bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease. Risk of complications in use and lower awareness about biodegradable stents among healthcare professionals in developing and developed regions are expected to hamper the growth of Biodegradable Drug Eluting Stents Market over the forecast period.